Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lyell Immunopharma (LYEL) Equity Average (2020 - 2025)

Historic Equity Average for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to $314.0 million.

  • Lyell Immunopharma's Equity Average fell 4275.93% to $314.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $314.0 million, marking a year-over-year decrease of 4275.93%. This contributed to the annual value of $518.9 million for FY2024, which is 3026.65% down from last year.
  • Per Lyell Immunopharma's latest filing, its Equity Average stood at $314.0 million for Q3 2025, which was down 4275.93% from $317.7 million recorded in Q2 2025.
  • Over the past 5 years, Lyell Immunopharma's Equity Average peaked at $1.0 billion during Q3 2021, and registered a low of -$313.3 million during Q1 2021.
  • Moreover, its 5-year median value for Equity Average was $676.3 million (2023), whereas its average is $611.4 million.
  • As far as peak fluctuations go, Lyell Immunopharma's Equity Average skyrocketed by 49633.37% in 2021, and later crashed by 4567.27% in 2025.
  • Lyell Immunopharma's Equity Average (Quarter) stood at $958.1 million in 2021, then fell by 13.72% to $826.6 million in 2022, then fell by 18.19% to $676.3 million in 2023, then tumbled by 32.46% to $456.8 million in 2024, then tumbled by 31.25% to $314.0 million in 2025.
  • Its Equity Average stands at $314.0 million for Q3 2025, versus $317.7 million for Q2 2025 and $359.7 million for Q1 2025.